# Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

> **NCT02054104** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Thoracic Sarcomas
- Thorasic Cancers
- Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
- Sarcoma
- Melanoma

## Interventions

- **BIOLOGICAL:** H1299 cell lysates
- **DRUG:** Cyclophosphamide
- **DRUG:** Celecoxib
- **BIOLOGICAL:** Iscomatrix adjuvant

## Key facts

- **NCT ID:** NCT02054104
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-03
- **Primary completion:** 2015-06-03
- **Final completion:** 2015-06-15
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Vaccine production halted in 2015, thus study is terminated.
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054104, "Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02054104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*